JAZZ - Jazz Pharmaceuticals Public Limited Company

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
133.87
+0.34 (+0.25%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close133.53
Open133.19
Bid95.82 x 100
Ask142.24 x 100
Day's Range132.82 - 134.97
52 Week Range99.28 - 163.75
Volume314,323
Avg. Volume470,347
Market Cap8.03B
Beta1.33
PE Ratio (TTM)20.62
EPS (TTM)6.49
Earnings DateNov 6, 2017 - Nov 10, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est179.10
Trade prices are not sourced from all markets
  • ACCESSWIRE3 days ago

    Corporate News Blog - RXi Pharma Collaborates with Gustave Roussy, Europe's Leading Cancer Centre

    Research Desk Line-up: Jazz Pharma Post Earnings Coverage LONDON, UK / ACCESSWIRE / November 15, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for RXi ...

  • See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.
    Markit4 days ago

    See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • ACCESSWIRE4 days ago

    Featured Company News - Adaptimmune Outlines Study Designs for Two T-Cell Clinical Trials - MAGE-A4 and NY-ESO SPEAR

    Research Desk Line-up: Jazz Pharma Post Earnings Coverage LONDON, UK / ACCESSWIRE / November 14, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Adaptimmune ...

  • See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.
    Markit5 days ago

    See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Thomson Reuters StreetEvents8 days ago

    Edited Transcript of JAZZ earnings conference call or presentation 7-Nov-17 9:30pm GMT

    Q3 2017 Jazz Pharmaceuticals PLC Earnings Call

  • PR Newswire9 days ago

    Jazz Pharmaceuticals Announces Participation in Three Upcoming Investor Conferences

    Jefferies London Healthcare Conference in London on Thursday, November 16, 2017 at 8:40 a.m. GMT / 3:40 a.m. EST.  Iain McGill, senior vice president, Jazz Pharmaceuticals Europe and rest of world, will provide an overview of the company and a business and financial update. Piper Jaffray 29th Annual Healthcare Conference in New York, NY on Tuesday, November 28, 2017 at 8:00 a.m. EST / 1:00 p.m. GMT.  Bruce Cozadd, chairman and chief executive officer, will provide an overview of the company and a business and financial update. Evercore ISI Biopharma Conference in Boston, MA on Wednesday, November 29, 2017 at 10:15 a.m. EST / 3:15 p.m. GMT.  Bruce Cozadd, chairman and chief executive officer, will provide an overview of the company and a business and financial update.

  • Jazz Pharmaceuticals (JAZZ) Q3 Earnings Top, 2017 View Cut
    Zacks10 days ago

    Jazz Pharmaceuticals (JAZZ) Q3 Earnings Top, 2017 View Cut

    Jazz Pharmaceuticals (JAZZ) earnings beat estimates while revenues miss the same in Q3. The company also cuts its guidance due to lower-than-expected sales from Xyrem.

  • See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.
    Markit11 days ago

    See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • American City Business Journalslast month

    All that Jazz: Why this Palo Alto drug maker is growing

    Jazz Pharmaceuticals plc is feeling the rhythm of growth. Fresh off winning Food and Drug Administration approval of a leukemia-fighting drug, the Ireland-domiciled, Palo Alto-based drug developer (JAZZ) soon will move into a new, 98,000-square-foot office building in Stanford Research Park, which it agreed to lease in early 2015 for $66 per square foot. Last month, it said it would pay more than $74 a square foot for a 100,000-square-foot structure on the site of its current home just down the street.

  • Capital Cubelast month

    ETFs with exposure to Jazz Pharmaceuticals Plc : October 11, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Jazz Pharmaceuticals Plc Here are 5 ETFs with the largest exposure to JAZZ-US. Comparing the performance and risk of Jazz Pharmaceuticals Plc with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Genocea Biosciences (GNCA) Jumps: Stock Rises 24.8%
    Zackslast month

    Genocea Biosciences (GNCA) Jumps: Stock Rises 24.8%

    Genocea Biosciences (GNCA) was a big mover last session, as the company saw its shares rise almost 25% on the day amid huge volumes.

  • Jazz Pharmaceuticals Plc breached its 50 day moving average in a Bullish Manner : JAZZ-US : October 3, 2017
    Capital Cube2 months ago

    Jazz Pharmaceuticals Plc breached its 50 day moving average in a Bullish Manner : JAZZ-US : October 3, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Jazz Pharmaceuticals Plc. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)

  • Capital Cube2 months ago

    ETFs with exposure to Jazz Pharmaceuticals Plc : September 25, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Jazz Pharmaceuticals Plc Here are 5 ETFs with the largest exposure to JAZZ-US. Comparing the performance and risk of Jazz Pharmaceuticals Plc with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • 3 Stocks That Are Absurdly Cheap Right Now
    Motley Fool2 months ago

    3 Stocks That Are Absurdly Cheap Right Now

    Looking for value in today's pricy market? These three stocks fit the bill.

  • See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.

    Jazz Pharmaceuticals PLC NASDAQ/NGS:JAZZ

  • Capital Cube2 months ago

    ETFs with exposure to Jazz Pharmaceuticals Plc : September 14, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Jazz Pharmaceuticals Plc Here are 5 ETFs with the largest exposure to JAZZ-US. Comparing the performance and risk of Jazz Pharmaceuticals Plc with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Jazz Pharmaceuticals Plc :JAZZ-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017
    Capital Cube2 months ago

    Jazz Pharmaceuticals Plc :JAZZ-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017

    Categories: Yahoo FinanceGet free summary analysis Jazz Pharmaceuticals Plc reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Jazz Pharmaceuticals Plc – Endo International Plc, Valeant Pharmaceuticals International Inc, Teva Pharmaceutical Industries Limited Sponsored ADR, Paratek Pharmaceuticals Inc, AmerisourceBergen Corporation and Novartis AG Sponsored ADR (ENDP-US, ... Read more (Read more...)

  • 3 Pharma/Biotech Sector Bargains for a Healthy Portfolio
    Zacks2 months ago

    3 Pharma/Biotech Sector Bargains for a Healthy Portfolio

    The biotech sector has turned around after its dismal performance in 2016 as uncertainty surrounding drug pricing control subsides. A few stocks are however still undervalued, which may gain going ahead.

  • Jazz Pharmaceuticals Plc – Value Analysis (NASDAQ:JAZZ) : September 12, 2017
    Capital Cube2 months ago

    Jazz Pharmaceuticals Plc – Value Analysis (NASDAQ:JAZZ) : September 12, 2017

    Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Jazz Pharmaceuticals Plc a score of 91. Our analysis is based on comparing Jazz Pharmaceuticals Plc with the following peers – Endo International Plc, Valeant Pharmaceuticals International Inc, Teva Pharmaceutical Industries Limited Sponsored ADR, Paratek Pharmaceuticals Inc, AmerisourceBergen Corporation and Novartis AG Sponsored ADR (ENDP-US, VRX-US, TEVA-US, ... Read more (Read more...)

  • PR Newswire2 months ago

    Fortune Magazine Names Jazz Pharmaceuticals 78th Fastest Growing Company for 2017

    DUBLIN, Sept. 12, 2017 /PRNewswire/ -- Jazz Pharmaceuticals plc (JAZZ) today announced that the company was named to Fortune magazine's list of fastest growing companies for 2017. In Fortune's annual rankings, Jazz was named the 78th fastest growing company. "We are honored to be recognized with some of the most innovative companies in the world," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals.

  • Jazz Pharmaceuticals Plc breached its 50 day moving average in a Bullish Manner : JAZZ-US : September 11, 2017
    Capital Cube2 months ago

    Jazz Pharmaceuticals Plc breached its 50 day moving average in a Bullish Manner : JAZZ-US : September 11, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Jazz Pharmaceuticals Plc. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)

  • Market Realist2 months ago

    Where Jazz Pharmaceuticals’ Erwinaze and Prialt Are Positioned after 2Q17

    In 2Q17, Jazz Pharmaceuticals’ (JAZZ) Erwinaze generated revenues of ~$49 million, which represents a ~1% fall YoY and a ~4% fall QoQ.

  • Market Realist2 months ago

    How Is Jazz’s Defitelio Positioned after 2Q17?

    In 2Q17, Jazz Pharmaceuticals’ (JAZZ) Defitelio generated revenues of ~$30 million, which represents a ~10% fall YoY and a ~17% fall QoQ.

  • Market Realist2 months ago

    This Could Drive Jazz Pharmaceuticals’ Revenue Growth

    In 2Q17, Jazz Pharmaceuticals’ (JAZZ) Xyrem generated revenues of ~$298 million, which represents ~6% growth YoY and ~10% growth QoQ.

  • Why Jazz Pharmaceuticals’ Vyxeos Could Boost Revenue Growth in 2018
    Market Realist2 months ago

    Why Jazz Pharmaceuticals’ Vyxeos Could Boost Revenue Growth in 2018

    In August 2017, JAZZ's Vyxeos liposome injection for the treatment of adult individuals with rapidly progressing or life t-AML received FDA approval.